Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...
2024 Germany's Merck KGaA agreed to sell its pigments unit to China's Global New Material International (GNMI) for 665 million euros ($721.46 million), the German diversified group said on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback